

# Norio Hanafusa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2664285/publications.pdf>

Version: 2024-02-01

18  
papers

560  
citations

1163117

8  
h-index

996975

15  
g-index

18  
all docs

18  
docs citations

18  
times ranked

812  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013). Therapeutic Apheresis and Dialysis, 2015, 19, 540-574.	0.9	275
2	Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis population. Kidney International Supplements, 2015, 5, 15-22.	14.2	70
3	Single Center Experience of Cell-Free and Concentrated Ascites Reinfusion Therapy in Malignancy Related Ascites. Therapeutic Apheresis and Dialysis, 2014, 18, 87-92.	0.9	36
4	Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. PLoS ONE, 2017, 12, e0177303.	2.5	36
5	Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. International Journal of Clinical Oncology, 2015, 20, 623-628.	2.2	33
6	Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study. JMIR Research Protocols, 2017, 6, e63.	1.0	33
7	Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrology Dialysis Transplantation, 2014, 29, 2316-2326.	0.7	29
8	The characteristics of the older dialysis population—heterogeneity and another type of altered risk factor patterns. Renal Replacement Therapy, 2017, 3, .	0.7	12
9	Is There a Role for Diaphoresis Therapy for Advanced Chronic Kidney Disease Patients?. , 2017, 27, 295-302.		10
10	Heterogeneity of clinical indices among the older dialysis population—a study on Japanese dialysis population. Renal Replacement Therapy, 2017, 3, .	0.7	7
11	Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. International Journal of Clinical Oncology, 2021, 26, 1130-1138.	2.2	5
12	Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3224-3232.	2.8	5
13	Efficacy of Substance Removal by Immunoabsorption With a Selective Plasma Separator. Therapeutic Apheresis and Dialysis, 2017, 21, 218-225.	0.9	3
14	Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 235-240.	1.8	2
15	Biochemical evaluation of processed ascites in patients undergoing cell-free and concentrated ascites reinfusion therapy. Therapeutic Apheresis and Dialysis, 2020, 24, 516-523.	0.9	2
16	Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19. Intestinal Research, 2021, , .	2.6	2
17	Strategies for the Super-Aged Dialysis Population: Survival Benefits or Alternative Goals?. Blood Purification, 2019, 47, 95-105.	1.8	0
18	Nephrology in Japan. , 2021, , 345-360.		0